BioSpace News Archive

Conference Call to be held Wednesday, March 24, 2021 at 5:00 pm EDT

Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Alan Colowick, M.D., to its board of directors. Dr. Colowick is an experienced biotech leader and has served in numerous executive and board roles.

HCCscreen TM achieved 88% sensitivity and 93% specificity, compared with 71% and 95%, respectively, by ultrasound plus AFP. In early-stage patients, the sensitivities of HCCscreen TM are 85% (tumor size of <3cm) and 96% (3-5 cm). The Company plans to initiate an NMPA registrational trial in China in Q2 2021.

Today, Health Canada updated the product monograph—or label—for the AstraZeneca and COVISHIELD COVID-19 vaccines to provide information on very rare reports of blood clots associated with low levels of blood platelets (i.e., thrombocytopenia) following immunization with the AstraZeneca vaccine

Rising demand to administer antibody rich blood, especially during COVID-19, has stimulated demand for checking quality and efficacy

Bacterial and viral collection is done in healthcare settings to diagnose the kind of disease an individual has.

Pharmacovigilance is a process refereeing to the detection, collection, prevention, and monitoring of negative effects that may occur because of the use of pharmaceutical products and other drugs.

– Initial data from Phase 1/2a trial of EOS-448 to be presented at American Association for Cancer Research Annual Meeting. Company to hold conference call at 8:00 am on April 12 th to discuss results –

Initiated Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras OXER1 Antagonist Preclinical R&D Program Acquired Changes to Board of Directors & Executive Team US$30M in gross proceeds from a private placement closed in November C$29.1M in proceeds from long-term loan from SALP in September

Fact.MR, Rockville MD: The global bone biopsy systems market study being conducted by market research firm Fact.MR projects a positive expansion outlook for 2021 and beyond.